Wednesday, July 8, 2026

Patent intelligence · US

US 12018011

Macrocyclic compounds and compositions, and methods of preparing and using the same

granted A61PA61P35/00
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 18
Applicant portfolio 132
Patent details — US 12018011

Quick answer

US 12018011 (Macrocyclic compounds and compositions, and methods of preparing and using the same) is held by Kura Oncology, Inc.. Status: granted. Granted Jun 25, 2024. Expires Jun 20, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
222
CPC classes
A61P, A61P35/00

More from Kura Oncology, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12410184

    Crystalline forms of a menin inhibitor

    Kura Oncology, Inc. · Expires Sep 4, 2045

    granted
  2. US 12377026

    Dental adhesive material kit

    KURARAY NORITAKE DENTAL INC. · Expires Jul 31, 2045

    granted
  3. US 12358210

    Resin composition for stereolithography

    KURARAY NORITAKE DENTAL INC. · Expires Jul 10, 2045

    granted
  4. US 12344691

    Resin composition for stereolithography

    KURARAY NORITAKE DENTAL INC. · Expires Jun 26, 2045

    granted
  5. US 12214061

    Adhesive composition for dental use

    KURARAY NORITAKE DENTAL INC. · Expires Jan 30, 2045

    granted
  6. US 12208148

    Dental restorative curable composition

    KURARAY NORITAKE DENTAL INC. · Expires Jan 23, 2045

    granted
  7. US 12145888

    Zirconia molded body and pre-sintered body capable of being sintered in short time

    KURARAY NORITAKE DENTAL INC. · Expires Nov 14, 2044

    granted
  8. US 12138325

    Dental composition

    KURARAY NORITAKE DENTAL INC. · Expires Nov 7, 2044

    granted

Frequently asked questions

What is US patent 12018011?

US 12018011 (Macrocyclic compounds and compositions, and methods of preparing and using the same) is held by Kura Oncology, Inc.. Status: granted. Granted Jun 25, 2024. Expires Jun 20, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 12018011?

Kura Oncology, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 132 pharmaceutical patents for this assignee.

When does US 12018011 expire?

Our index shows an expiration date of Jun 20, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.